There is growing acceptance of traditional Chinese medicines (TCMs) as potential sources of clinical agents based on the demonstrated efficacies of numerous bioactive compounds first identified in TCM extracts, such as paclitaxel, camptothecin, and artemisinin. However, there are several challenges to achieving the full clinical potential of many TCMs, particularly the generally high hydrophobicity and low bioavailability. Recently, however, numerous studies have attempted to circumvent the limited in vivo activity and systemic toxicity of TCM ingredients by incorporation into nanoparticle-based delivery systems. Many of these formulations demonstrate improved bioavailability, enhanced tissue targeting, and greater in vivo stability compared to the native compound. This review summarizes nanoformulations of the most promising and extensively studied TCM compounds to provide a reference for further research. Combining these natural compounds with nanotechnology-based delivery systems may further improve the clinical utility of these agents, in turn leading to more intensive research on traditional medicinal compounds.

中文翻译：

---

纳米技术用于中药有效成分的研究进展。

基于中药提取物中首次鉴定出的多种生物活性化合物（如紫杉醇，喜树碱和青蒿素）的功效已被证明，中药（TCMs）已成为临床药物的潜在来源。但是，要实现许多中药的全部临床潜能，尤其是通常的高疏水性和低生物利用度，存在若干挑战。然而，最近，许多研究试图通过掺入基于纳米颗粒的递送系统来规避中药成分的有限的体内活性和全身毒性。这些配方中的许多配方均显示出更高的生物利用度，增强的组织靶向性以及更高的体内活性与天然化合物相比具有稳定性。这篇综述总结了最有前途和研究最广泛的中药化合物的纳米制剂，为进一步研究提供参考。将这些天然化合物与基于纳米技术的递送系统结合在一起，可以进一步改善这些药物的临床效用，进而导致对传统药用化合物的更深入研究。